• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » CardioNet overbills, BioTelemetry pays $6m

CardioNet overbills, BioTelemetry pays $6m

March 23, 2015 By Mark Hollmer

UPDATED April 3, 2015, with comment from BioTelemetry.

BioTelemetryCardioNet overbills, BioTelemetry pays $6m on fraud charges agreed to fork over $6.4 million to settle federal charges that its CardioNet subsidiary overbilled Medicare for unnecessary outpatient services.

CardioNet, which re-branded itself in July 2013 as BioTelemetry after its $11.6 million acquisition of Biotel in 2010, provides remote cardiac monitoring services.

The U.S. Justice Dept. charged the Malvern, Pa.-based company with breaking the False Claims Act by billing Medicare for excessive or unneeded mobile cardiac outpatient telemetry services, despite knowing that its MCOT services are not eligible for reimbursement for patients who only had mild or moderate heart palpitations.

CardioNet had allegedly used an incorrect diagnostic code to ensure its mobile cardiac outpatient telemetry devices would win Medicare reimbursement at a higher rate, the feds alleged. BioTelemetry admitted no liability in agreeing to the settlement, according to the Justice Dept.

The BioTelemetry deal stemmed from a federal probe of another remote monitoring company, Illinois-based LifeWatch Services. Back in 2012, LifeWatch agreed to pay $18.5 million to settle allegations that it submitted bogus diagnostic information to access more Medicare dollars.

CardioNet in 2010 won a shareholder lawsuit accusing it and its management of misleading investors over its prospects for higher Medicare reimbursement.

“We are thankful to have the investigation completed. As previously discussed, the company was not the original target of the investigation and was fully cooperative throughout this inquiry. While we believe the facts did not support the government’s allegations, we entered into settlement negotiations due to the cost and burden of the investigation on the company. As the terms became more reasonable, we felt that it was in the best interest of the company and our shareholders to settle the case. Under the terms of the agreement, there was no determination of liability and BioTelemetry made no admission of wrong doing. In addition, the company was not required to enter into a corporate integrity agreement,” president & CEO Joseph Capper said in prepared remarks. “We can now put this matter behind us and focus completely on executing our strategy in an ethical and compliant fashion, as has always been the case.”

Filed Under: Legal News, News Well Tagged With: BioTelemetry Inc., CardioNet Inc., Remote Patient Monitoring, U.S. Justice Dept. (DOJ)

More recent news

  • Autonomix picks up key nerve ablation catheter patent
  • Affluent Medical can move to pivotal phase of artificial urinary sphincter study
  • Globus Medical announces $500M share repurchase program
  • Cook Medical warns of issue with angiographic catheter
  • Virtuoso Surgical reports first cases with robotic endoscopy system, plans FDA IDE submission

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy